3 ms·
A couple of things I found interesting from the study: - The eligible participants in the study tended to be over the age of 65 (Moderna median = 66, Pfizer me
by thatsamonad 5y ago
A couple of things I found interesting from the study:
- The eligible participants in the study tended to be over the age of 65 (Moderna median = 66, Pfizer median = 68)
- The Pfizer cohort (738 eligible participants) was almost twice the size of the Moderna cohort (476 eligible participants)
Would these factors have skewed the results at all? To me it seems like the study strongly indicates a difference for those age 65 and over but not necessarily for younger groups.
There is also still evidence of strong protection from hospitalization and death with both vaccines so I don’t think anyone necessarily needs to be regretting the fact that they got a pair of Pfizer shots at this point.
Source study: https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm#T1_down https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm#T1_down
- kristofferR 5y agoIt's consistent with basically all non-US research too though, this is just one study out of many with consistent results. The evidence for Moderna providing a larger immune response due to the 3x dosage and longer intervals between doses isn't really in dispute at this point.
- deleted 5y ago[deleted]
- dehrmann 5y ago> due to the 3x dosage and longer intervals between doses Aren't these just hypotheses? They're very plausible, but I wouldn't go as far as saying the mechanism isn't in dispute. It's the outcome that isn't in dispute.
- omegalulw 5y agoI think they are. The third factor that differs between the two is the design of the vaccine. Presumably they both target the spike protein and use mRNA so they should be similar but still different nonetheless.
- kristofferR 5y agoThat's fair.